FY2028 Earnings Forecast for ESLA Issued By Zacks Research

Estrella Immunopharma, Inc. (NASDAQ:ESLA) – Analysts at Zacks Research issued their FY2028 EPS estimates for shares of Estrella Immunopharma in a research note issued to investors on Tuesday, July 14th. Zacks Research analyst D. Bautz anticipates that the company will post earnings per share of ($0.31) for the year. The consensus estimate for Estrella Immunopharma’s current full-year earnings is ($0.39) per share.

Separately, Weiss Ratings raised Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Estrella Immunopharma Stock Performance

Shares of NASDAQ ESLA opened at $0.77 on Thursday. Estrella Immunopharma has a fifty-two week low of $0.77 and a fifty-two week high of $3.15. The company has a 50 day simple moving average of $1.06 and a two-hundred day simple moving average of $1.21. The company has a market capitalization of $33.21 million, a price-to-earnings ratio of -2.27 and a beta of 0.85.

Estrella Immunopharma (NASDAQ:ESLA) last posted its quarterly earnings data on Saturday, May 16th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.03.

Hedge Funds Weigh In On Estrella Immunopharma

Large investors have recently modified their holdings of the stock. Quadrature Capital Ltd bought a new position in Estrella Immunopharma in the 4th quarter worth about $43,000. State Street Corp increased its stake in Estrella Immunopharma by 93.5% during the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock valued at $67,000 after purchasing an additional 20,900 shares in the last quarter. XTX Topco Ltd raised its holdings in Estrella Immunopharma by 376.9% in the fourth quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after buying an additional 39,099 shares during the last quarter. Marshall Wace LLP purchased a new position in Estrella Immunopharma in the fourth quarter worth about $88,000. Finally, Geode Capital Management LLC lifted its stake in shares of Estrella Immunopharma by 8.2% in the fourth quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock worth $171,000 after buying an additional 8,318 shares in the last quarter. Hedge funds and other institutional investors own 0.35% of the company’s stock.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.